FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

| OMB APPROVAL | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number: | 3235-0104 | | | | | | |
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | 1 | | | | |
|--|---|--|---|--|--------------------------|---|---|---|
| 1. Name and Address of Chen Daniel Sh | 2. Date of Event Requiring Stater Month/Day/Yea 09/17/2019 | ment | 3. Issuer Name and Ticker or Trading Symbol IGM Biosciences, Inc. [IGMS] | | | | | |
| (Last) (Firs | | | Relationship of Reporting Perso (Check all applicable) Director | 10% Owne | r (Mo | 5. If Amendment, Date of Original Filed (Month/Day/Year) | | |
| 325 E. MIDDLEFI | | | X Officer (give title below) | Other (spec | ′ 6. lr | 6. Individual or Joint/Group Filing (Check Applicable Line) | | |
| MOUNTAIN CA 94043 | | | | Chief Medical O | fficer |) | X Form filed by One Reporting Person Form filed by More than One Reporting Person | |
| (City) (Sta | te) (Zip) | | | | | | | |
| | ٦ | Гable I - Nor | n-Derivat | tive Securities Beneficiall | y Owned | | | |
| 1. Title of Security (Instr. 4) | | | | 2. Amount of Securities Beneficially Owned (Instr. 4) | | | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | |
| | | | | | (| | | |
| Common Stock | | | | 116,518 ⁽¹⁾ | D | | | |
| Common Stock | (e. | | | 116,518 ⁽¹⁾ re Securities Beneficially ants, options, convertible | D Owned | s) | | |
| Common Stock 1. Title of Derivative S | | | ls, warra | re Securities Beneficially ants, options, convertible | D Owned securities | 4. Conversion or Exercise | 5. Ownership Form: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
| | | g., puts, cal 2. Date Exerc Expiration Da | ls, warra | re Securities Beneficially ants, options, convertible 3. Title and Amount of Securit Underlying Derivative Security | D Owned securities | 4. Conversion | Ownership | Beneficial Ownership |

Explanation of Responses:

- 1. 58,259 of the shares subject to this grant are subject to forfeiture until August 1, 2020 in accordance with the Reporting Person's Restricted Stock Grant Agreement.
- 2. 1/4 of the shares subject to the option shall vest on August 1, 2019 and an additional 1/48 of the shares subject to the option shall vest monthly thereafter subject to Reporting Person remaining a service provider through each such date.

Remarks:

/s/ Misbah Tahir, by power of attorney 09/17/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of IGM Biosciences, Inc. (the "Company"), hereby constitutes and appoints Fred Schwarzer and Misbah Tahir, and each of them, as the undersigned's true and lawful attorney-in-fact to:

- 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended). This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 17th day of September, 2019.

DANIEL S. CHEN

/S/ Daniel S. Chen